Mubadala Investment Company launched Mubadala Bio, a new pharma company focused on boosting the UAE’s drug manufacturing capabilities and improving access to essential medicines and medical devices, according to a press release. The firm will focus on developing and manufacturing products aimed at disease prevention, diagnostics, treatment, and long-term care, that address both regional and global health challenges.

Mubadala Bio’s portfolio includes 10 facilities across Asia, Africa, and Europe, including six in the UAE. These sites collectively have the capacity to produce over 2.5 bn tablets and capsules, and 120 mn units of IV solutions and injectables per year. The total facility footprint is 110k sqm, serving more than 100 countries.

Looking ahead, Mubadala Bio plans to form strategic partnerships with leading global pharma firms and academic institutions, in a bid to accelerate growth in the biopharma sector, expand local manufacturing, and develop national talent. The company is debuting publicly at the Make it in the Emirates Forum 2025.

REMEMBER- Mubadala has been ramping up its investments in healthcare and pharma. In December 2024, it acquired an 80% stake in Abu Dhabi based healthcare logistics firm Global Medical Supply Chain and pharma firm Al Ittihad Drug Store. It also took a minority stake in US-based healthcare tech firm Zelis and invested an undisclosed amount in India’s Manipal Health Enterprises in February 2024.

Tags: